Neutrophil and Monocyte Alterations in Chronic Dialysis Patients

American Journal of Kidney Diseases

Volumn 9, Issue 5, 1987, Pages 381-395

  Lewis, Sharon L ^a   Van Epps, Dennis E ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

chemotactic factors; Dialysis; hemodialysis; infection; monocyte; neutrophil; peritoneal dialysis

Indexed keywords

BLOOD AND HEMOPOIETIC SYSTEM; ETIOLOGY; HEMODIALYSIS; HUMAN; HUMAN CELL; KIDNEY; MONOCYTE; NEUTROPHIL; PERITONEAL DIALYSIS; PERITONEUM; REVIEW;

EID: 0023183849     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(87)80141-5     Document Type: Article

References (106)

1. Renal failure and infection
2. Demographic analysis.: Endstage renal disease and its treatment in the United States
3. Incidence and type of infections occurring in 445 chronic hemodialysis
4. Bacteremic infection in hemodialysis
5. Morbidity of infection in chronic hemodialysis
6. Maintenance hemodialysis.: Survival beyond the first decade
7. Mortality risk factors in patients treated by chronic hemodialysis
8. Patients surviving 10 years of hemodialysis
9. Long dialysis.: A review of 15 years experience in one centre 1968-1983
10. Impaired neutrophil response to bacterial infection in dialyzed patients
11. Host defense mechanisms in continuous ambulatory peritoneal dialysis
12. Profound neutropenia during the early phase of hemodialysis
13. Leukocyte dynamics with three types of hemodialyzers
14. Mechanisms of recovery from neutropenia induced by hemodialysis
15. Hemodialysis leukopenia.: Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes
16. Hemodialysis leukopenia and complement function with different dialyzers
17. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis
18. Pulmonary bed sequestration of neutrophils during hemodialysis
19. Acute cardiopulmonary decompensation and complement activation during hemodialysis
20. The effect of hemodialysis and C5a des arg on neutrophil subpopulations
21. A defect in the oxidative metabolism of human polymorphonuclear leukocyte that remain in circulation early in hemodialysis
22. Automated cytochemical staining and inflammation.: Further assessment of the left shift
23. Effects of complement activation by hemodialysis membranes
24. An introduction to biocompatibility
25. Hemodialysis-induced leucopenia and activation of complement.: Effects of different membranes
26. Leukopenia, hypoxia, and complement function with different dialysis membranes
27. Modified neutropenic response related to different dialysis membranes
28. Membrane-induced leucopenia
29. Two special properties of poly acrylonitrile membrane suitable for reuse and biocompatibility
30. Hemodialysis-associated neutropenia and hypoxemia.: The effect of dialyzer membrane materials
31. Complement activation by hemodialysis membrane
32. Leukopenia and hypoxemia.: Unrelated effects of hemodialysis
33. A study on hemodialysis leukopenia using various dialyzers
34. Symptoms and activation of granulocytes and complement with 2 dialysis membranes
35. Anaphylatoxin formation during hemodialysis.: Effects of different dialyzer membranes
36. Depressed neutrophil chemotaxis associated in patients with chronic renal failure and after renal transplantation
37. The effect of hemodialysis on neutrophil chemotactic responsiveness
38. The effect of hemodialysis on neutrophil chemotactic responsiveness
39. Reversal of hemodialysis granulocytopenia and pulmonary leukostasis.: A clinical manifestation of selective down regulation of granulocyte responses to C5a des argo
40. Lymphocyte and granulocyte function in zinc-treated and zinc-deficient hemodialysis patients
41. Influence of hemodialysis on plasma chemotactic activity and the chemotactic responsiveness of polymorphonuclear neutrophils
42. Immunologic abnormalities in hemodialysis patients.: Improvement after pyridoxine therapy
43. The neutrophil function of uremic patients treated by hemodialysis or CAPD
44. Granulocyte function using nandrolene decanoate in patients on maintenance hemodialysis
45. Leukocyte metabolism and function in uremia
46. Comparison of chemotactic receptors on leukocytes from chronic hemodialysis and peritoneal dialysis patients
47. C5a receptor modulation on neutrophils and monocytes from chronic hemodialysis and peritoneal dialysis patients
48. Neutrophil adhesiveness during prostacyclin and heparin hemodialysis
49. Immune and phagocytic function in patients on maintenance dialysis and post-transplantation
50. Phagocytosis and candidacidal activity of polymorphonuclear leukocytes in uremia
51. Defective immune and phagocytic functions in uremia and renal transplantation
52. Granulocyte function in patients with chronic renal failure.: Surface adherence, phagocytosis
53. Phagocytosis and nitroblue tetrazolium reduction in uremia
54. Kinetic studies of phagocytosis.: II. The serum independent uptake of IgG-coated particles by polymorphonuclear leukocytes from uremic patients on regular dialysis treatment
55. Depressed polymorphonuclear leukocyte functions associated with normal cytotoxic functions of T and natural killer cells during chronic hemodialysis
56. Leukocyte phagocytosis and serum bactericidal activity in chronic renal failure
57. Chemiluminescence and superoxide anion production by leukocytes from chronic hemodialysis patients
58. Polymorphonuclear leukocyte defects in chronic hemodialysis patients
59. Leukocyte function tests during hemodialysis with different dialysis membranes
60. Granulocyte adherence in uremia and hemodialysis
61. Chemotaxis of the polymorphonuclear leukocyte and delayed hypersensitivity in uremia
62. Hemodialysis leukopenia and polymorph random mobility—A possible correlation
63. Pathology of chemotaxis and random migration
64. Chemotactic deactivation of human neutrophils.: Evidence for nonspecific and specific components
65. Selective neutrophil desensitization to chemotactic factors
66. Chemotactic deactivation of human neutrophils.: Relationship to loss of cytotoxin receptor function and temporal nature of phenomenon
67. Chemotactic peptide receptor modulation in polymorphonuclear leukocytes
68. Specific binding of synthetic chemotactic peptides to rabbit peritoneal neutrophils.: Effects on dissociability of bound peptide, receptor activity and subsequent biologic responsiveness (deactivation)
69. Deactivation of human neutrophil chemotaxis by chemoattractants.: Effect on receptors for the chemotactic factor f-Met-Leu-Phe
70. Intracellular control of human neutrophil secretion. II. Stimulus specificity of desensitization induced by six different soluble and particulate stimuli
71. Chemotactic deactivation of human neutrophils.: Protective influence of phenylbutazone
72. Neutrophil dysfunction during the course of intra-abdominal infection
73. Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation
74. Neutrophil dysfunction in sepsis. III. Degranulation as a mechanism for nonspecific deactivation
75. Complementinduced expression of cryptic receptors on the neutrophil surface.: A mechanism for regulation of acute inflammation in trauma
76. Development of the adult respiratory distress syndrome.: Progressive alteration of neutrophil chemotactic secretory processes
77. Prostaglandin and complement interaction in clinical acute respiratory failure
78. Granulocyte activation by endotoxin. II. Role of granulocyte adherence, aggregation, and effect of cytochalasin B, and comparison with formylated chemotactic peptide-induced stimulation
79. Role of cell surface contact in the kinetics of superoxide production by granulocytes
80. Some aspects of cellular immunity in untreated and maintenance hemodialysis patients
81. Impairment of phagocytic activity of macrophages as studied by skin window tests
82. Impaired phagocytic activity of human monocytes in respect to reduced antibacterial resistance to uremia
83. Altered leukocyte chemiluminescence during dialysis
84. Leukocyte C5a receptor modulation during hemodialysis and following exposure to dialysis membranes
85. Density changes in leukocytes following hemodialysis or exposure to chemotactic factors
86. Suppressor cell activity of peripheral mononuclear cells from patients undergoing chronic hemodialysis
87. Cellular composition of peritoneal effluent.: Response to bacterial peritonitis
88. Immunodeficiency in chronic renal insufficiency
89. Output of peritoneal cells during peritoneal dialysis
90. Output of peritoneal cells into peritoneal dialysate
91. Treatment of peritonitis in patients on CAPD.: No longer a controversy
92. Analysis of peritoneal macrophages in continous ambulatory peritoneal dialysiS patients
93. Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro
94. Bacterial growth and killing in chronic ambulatory peritoneal dialysis fluids
95. Peritoneal macrophages and opsonin.: Antibacterial defense in patients undergoing chronic peritoneal dialysis
96. Opsonic deficiency of peritoneal dialysis effluent in continuous ambulatory peritoneal dialysis
97. Intracellular survival of Candida albicans in peritoneal macrophages from chronic peritoneal dialysis patients
98. Bactericidal and opsonic activity of cirrhotic ascites and nonascitic peritoneal fluid
99. Host defense mechanisms of the peritoneal cavity and continuous ambulatory peritoneal dialysis
100. N-formyl-methionyl-leucylphenylalanine binding, superoxide release, and chemotactic responses of human blood monocytes that repopulate the circulation during leukapheresis
101. Chemotactic deactivation of human neutrophils.: Possible relationship to stimulation of oxidative metabolism